Ian Charles Parrag

This inventor holds 9 USPTO granted patents and 16 published patent applications. Top assignee: Ripple Therapeutics Corporation. Active years: 2020-2025.

USPTO Granted Patents = 9 (Patent Applications = 16)

% Patents Active = 100.0

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 16(Granted Patents)

Location History:

Toronto, CA (2022)
Mississauga, CA (2020 - 2023)

Company Filing History:

9 out of 9

Ripple Therapeutics Corporation

patents

Years Active: 2020-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12509469 - Compositions and methods for the treatment of pain and dependence disorders (2025-12-30),

2. 12473326 - Crystalline forms of dexamethasone dimers and uses thereof (2025-11-18),

3. 11612567 - Ocular inserts comprising a covalently linked steroid dimer (2023-03-28),

4. 11464914 - Intravitreal injector (2022-10-11),

5. 11279729 - Heterodimer compositions and methods for the treatment of ocular disorders (2022-03-22),

6. 10959954 - Dexamethasone prodrug compositions and uses thereof (2021-03-30),

7. 10945958 - Dexamethasone prodrug compositions and uses thereof (2021-03-16),

8. 10632075 - Glass formulations and uses thereof (2020-04-28),

9. 10588862 - Dexamethasone prodrug compositions and uses thereof (2020-03-17),

Title: Innovations by Ian Charles Parrag

Introduction

Ian Charles Parrag is a notable inventor based in Mississauga, Canada. He has made significant contributions to the field of ocular therapeutics, holding a total of seven patents. His work focuses on developing advanced solutions for eye care, showcasing his commitment to improving patient outcomes.

Latest Patents

Among his latest patents is the "Ocular inserts comprising a covalently linked steroid dimer." This patent relates to compounds and compositions designed for the sustained release of ocular therapeutics. Another significant invention is the "Intravitreal injector," which includes needle assemblies for the precise and accurate intravitreal injection of an implant into a patient's eye. These innovations aim to enhance treatment efficacy while minimizing potential damage to the eye.

Career Highlights

Ian is currently associated with Ripple Therapeutics Corporation, where he continues to push the boundaries of ocular treatment technologies. His expertise and innovative mindset have positioned him as a key player in the field.

Collaborations

Ian collaborates with talented individuals such as Matthew Alexander John Statham and Kyle Giovanni Battiston, contributing to a dynamic team focused on advancing ocular health solutions.

Conclusion

Ian Charles Parrag's contributions to ocular therapeutics through his patents and collaborations reflect his dedication to innovation in eye care. His work continues to pave the way for improved treatments and patient care in the field.